Literature DB >> 18450758

Characterization of molecular mechanisms underlying mutations in dystrophic epidermolysis bullosa using site-directed mutagenesis.

David T Woodley1, Yingping Hou, Sabrina Martin, Wei Li, Mei Chen.   

Abstract

Type VII collagen (C7) is a major component of anchoring fibrils, structures that mediate epidermal-dermal adherence. Mutations in gene COL7A1 encoding for C7 cause dystrophic epidermolysis bullosa (DEB), a genetic mechano-bullous disease. The biological consequences of specific COL7A1 mutations and the molecular mechanisms leading to DEB clinical phenotypes are unknown. In an attempt to establish genotype-phenotype relationships, we generated four individual substitution mutations that have been associated with recessive DEB, G2049E, R2063W, G2569R, and G2575R, and purified the recombinant mutant proteins. All mutant proteins were synthesized and secreted as a 290-kDa mutant C7 alpha chain at levels similar to wild type C7. The G2569R and G2575R glycine substitution mutations resulted in mutant C7 with increased sensitivity to protease degradation and decreased ability to form trimers. Limited proteolytic digestion of mutant G2049E and R2063W proteins yielded aberrant fragments and a triple helix with reduced stability. These two mutations next to the 39-amino acid helical interruption hinge region caused local destabilization of the triple-helix that exposed an additional highly sensitive proteolytic site within the region of the mutation. Our functional studies demonstrated that C7 is a potent pro-motility matrix for skin human keratinocyte migration and that this activity resides within the triple helical domain. Furthermore, G2049E and R2063W mutations reduced the ability of C7 to support fibroblast adhesion and keratinocyte migration. We conclude that known recessive DEB C7 mutations perturb critical functions of the C7 molecule and likely contribute to the clinical phenotypes of DEB patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18450758      PMCID: PMC2440610          DOI: 10.1074/jbc.M709452200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  The carboxyl terminus of type VII collagen mediates antiparallel dimer formation and constitutes a new antigenic epitope for epidermolysis Bullosa acquisita autoantibodies.

Authors:  M Chen; D R Keene; F K Costa; S H Tahk; D T Woodley
Journal:  J Biol Chem       Date:  2001-03-27       Impact factor: 5.157

2.  Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes.

Authors:  Roslyn Varki; Sara Sadowski; Jouni Uitto; Ellen Pfendner
Journal:  J Med Genet       Date:  2006-09-13       Impact factor: 6.318

3.  Molecular basis of dystrophic epidermolysis bullosa: mutations in the type VII collagen gene (COL7A1).

Authors:  A Järvikallio; L Pulkkinen; J Uitto
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

4.  Ultraviolet A irradiation upregulates type VII collagen expression in human dermal fibroblasts.

Authors:  M Chen; M J Petersen; H L Li; X Y Cai; E A O'Toole; D T Woodley
Journal:  J Invest Dermatol       Date:  1997-02       Impact factor: 8.551

5.  Anchoring fibrils contain the carboxyl-terminal globular domain of type VII procollagen, but lack the amino-terminal globular domain.

Authors:  G P Lunstrum; H J Kuo; L M Rosenbaum; D R Keene; R W Glanville; L Y Sakai; R E Burgeson
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

6.  The tissue form of type VII collagen is an antiparallel dimer.

Authors:  N P Morris; D R Keene; R W Glanville; H Bentz; R E Burgeson
Journal:  J Biol Chem       Date:  1986-04-25       Impact factor: 5.157

7.  The phagokinetic tracks of 3T3 cells.

Authors:  G Albrecht-Buehler
Journal:  Cell       Date:  1977-06       Impact factor: 41.582

Review 8.  Molecular basis for the dystrophic forms of epidermolysis bullosa: mutations in the type VII collagen gene.

Authors:  J Uitto; A M Christiano
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

9.  Human type VII collagen: cDNA cloning and chromosomal mapping of the gene.

Authors:  M G Parente; L C Chung; J Ryynänen; D T Woodley; K C Wynn; E A Bauer; M G Mattei; M L Chu; J Uitto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

10.  Type VII collagen forms an extended network of anchoring fibrils.

Authors:  D R Keene; L Y Sakai; G P Lunstrum; N P Morris; R E Burgeson
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more
  12 in total

1.  Dominant-negative effects of COL7A1 mutations can be rescued by controlled overexpression of normal collagen VII.

Authors:  Anja Fritsch; Sashko Spassov; Susanne Elfert; Andreas Schlosser; Yannick Gache; Guerrino Meneguzzi; Leena Bruckner-Tuderman
Journal:  J Biol Chem       Date:  2009-09-02       Impact factor: 5.157

Review 2.  SMRT compounds correct nonsense mutations in primary immunodeficiency and other genetic models.

Authors:  Richard A Gatti
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

3.  Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.

Authors:  Olivier Bornert; Tobias Kühl; Jeroen Bremer; Peter C van den Akker; Anna Mg Pasmooij; Alexander Nyström
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

4.  Bone marrow transplant with post-transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts.

Authors:  C L Ebens; J A McGrath; K Tamai; A Hovnanian; J E Wagner; M J Riddle; D R Keene; T E DeFor; R Tryon; M Chen; D T Woodley; K Hook; J Tolar
Journal:  Br J Dermatol       Date:  2019-06-28       Impact factor: 9.302

5.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

6.  Intravenously Administered Recombinant Human Type VII Collagen Derived from Chinese Hamster Ovary Cells Reverses the Disease Phenotype in Recessive Dystrophic Epidermolysis Bullosa Mice.

Authors:  Yingping Hou; Lin T Guey; Timothy Wu; Robert Gao; Jon Cogan; Xinyi Wang; Elizabeth Hong; Weihuang Vivian Ning; Douglas Keene; Nan Liu; Yan Huang; Craig Kaftan; Bruce Tangarone; Igor Quinones-Garcia; Jouni Uitto; Omar L Francone; David T Woodley; Mei Chen
Journal:  J Invest Dermatol       Date:  2015-07-23       Impact factor: 8.551

7.  Characterization of mutant type VII collagens underlying the inversa subtype of recessive dystrophic epidermolysis bullosa.

Authors:  David T Woodley; Jon Cogan; Daniel Mosallaei; Kaitlyn Yim; Mei Chen
Journal:  J Dermatol Sci       Date:  2021-09-23       Impact factor: 4.563

8.  Topical application of recombinant type VII collagen incorporates into the dermal-epidermal junction and promotes wound closure.

Authors:  Xinyi Wang; Pedram Ghasri; Mahsa Amir; Brian Hwang; Yingpin Hou; Michael Khalili; Michael Khilili; Andrew Lin; Douglas Keene; Jouni Uitto; David T Woodley; Mei Chen
Journal:  Mol Ther       Date:  2013-05-14       Impact factor: 11.454

9.  Collagen VII plays a dual role in wound healing.

Authors:  Alexander Nyström; Daniela Velati; Venugopal R Mittapalli; Anja Fritsch; Johannes S Kern; Leena Bruckner-Tuderman
Journal:  J Clin Invest       Date:  2013-07-08       Impact factor: 14.808

10.  Two novel mutations on exon 8 and intron 65 of COL7A1 gene in two Chinese brothers result in recessive dystrophic epidermolysis bullosa.

Authors:  Ying Lin; Xue-Jun Chen; Wei Liu; Bo Gong; Jun Xie; Jun-Hao Xiong; Jing Cheng; Xi-Ling Duan; Zhao-Chun Lin; Lu-Lin Huang; Hui-Ying Wan; Xiao-Qi Liu; Lin-Hong Song; Zheng-Lin Yang
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.